Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.
Scientists at ORNL developed a competitive, eco-friendly alternative made without harmful blowing agents.
Oak Ridge National Laboratory scientists designed a recyclable polymer for carbon-fiber composites to enable circular manufacturing of parts that boost energy efficiency in automotive, wind power and aerospace applications.
ORNL has been selected to lead an Energy Frontier Research Center, or EFRC, focused on polymer electrolytes for next-generation energy storage devices such as fuel cells and solid-state electric vehicle batteries.
Five technologies invented by scientists at the Department of Energy’s Oak Ridge National Laboratory have been selected for targeted investment through ORNL’s Technology Innovation Program.
Oak Ridge National Laboratory researchers have retrofitted a commercial refrigeration container designed to ensure COVID-19 vaccines remain at ultra-low temperatures during long transport and while locally stored.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
Researchers at ORNL designed a novel polymer to bind and strengthen silica sand for binder jet additive manufacturing, a 3D-printing method used by industries for prototyping and part production.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.